F10抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: A431 cells, Primary antibody: P07653(F10 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

The F10 antibody is a monoclonal antibody initially developed for its targeting specificity toward a tumor-associated antigen, primarily explored in cancer research and therapeutic contexts. First characterized in the early 2000s, F10 was identified through hybridoma technology, leveraging its ability to bind selectively to cell surface epitopes overexpressed in certain malignancies, such as melanoma and breast cancer. Its antigen target, though not fully elucidated in early studies, is suggested to involve glycoprotein or glycolipid structures linked to tumor progression and metastasis.

F10 gained attention for its potential in diagnostic imaging and targeted therapy due to its high affinity and low cross-reactivity with normal tissues. Preclinical studies highlighted its utility in antibody-drug conjugates (ADCs) and radioimmunotherapy, where it demonstrated efficacy in tumor regression in murine models. However, clinical translation faced challenges, including variable antigen expression across patient populations and immune-related adverse effects.

Recent advancements in antibody engineering have revived interest in F10. with efforts to humanize its structure to reduce immunogenicity and enhance pharmacokinetics. Ongoing research explores its role in combination therapies and bispecific antibody formats, aiming to overcome resistance mechanisms in solid tumors. Despite limited commercial development to date, F10 remains a model for studying tumor-targeting strategies and antibody optimization.